Segment Information (Tables)

6 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Components of Segment Revenues and Adjusted EBITDA

Segment revenues and Adjusted EBITDA consisted of the following:

	Three Months Ended June 30,
	2023						2022
				Segment						Segment
	Segment			Adjusted			Segment			Adjusted
	Revenues			EBITDA			Revenues			EBITDA(4)
Assessment, Permitting and Response	$	61,411		$	13,833		$	50,037		$	10,809
Measurement and Analysis		50,055	(1)		10,789			42,224	(1)		7,047		(3)
Remediation and Reuse		47,635			6,043			47,649			7,056
Total Operating Segments		159,101			30,665			139,910			24,912
Corporate and Other		—			(9,474	)		—			(8,399	)
Total	$	159,101		$	21,191		$	139,910		$	16,513
	Six Months Ended June 30,
	2023						2022
				Segment						Segment
	Segment			Adjusted			Segment			Adjusted
	Revenues			EBITDA			Revenues			EBITDA(4)
Assessment, Permitting and Response	$	113,625		$	28,099		$	95,637		$	20,432
Measurement and Analysis		92,582	(2)		17,176			81,985	(2)		13,369		(3)
Remediation and Reuse		84,322			11,321			96,968			15,049
Total Operating Segments		290,529			56,596			274,590			48,850
Corporate and Other		—			(18,802	)		—			(15,886	)
Total	$	290,529		$	37,794		$	274,590		$	32,964

_____________________________________

(1) Includes revenue of $2.4 million and $3.4 million from the Discontinuing Specialty Lab, for the three months ended June 30, 2023 and June 30, 2022, respectively.

(2) Includes revenue of $3.9 million and $9.0 million from the Discontinuing Specialty Lab, for the six months ended June 30, 2023 and June 30, 2022, respectively.
(3) Includes Adjusted EBITDA loss of $(0.9) million and Adjusted EBITDA of $0.4 million from the Discontinuing Specialty Lab for the three and six months ended June 30, 2022, respectively.

(4) Includes the add back of start-up losses and investment in new services of $0.9 million and $1.7 million for the three and six months ended June 30, 2022, respectively .

Reconciliation of Segment Measure to Net Loss

Presented below is a reconciliation of the Company’s segment measure to net loss:

	For the Three Months Ended June 30,								For the Six Months Ended June 30,
	2023				2022				2023				2022
Total	$	21,191			$	16,513			$	37,794			$	32,964
Interest expense, net		(1,877	)			(1,518	)			(3,418	)			(2,610	)
Income tax expense		(151	)			(831	)			(1,518	)			(2,100	)
Depreciation and amortization		(11,398	)			(12,280	)			(21,953	)			(24,424	)
Stock-based compensation		(11,090	)			(10,932	)			(24,125	)			(21,357	)
Start-up losses and investment in new services		—				(885	)			—				(1,671	)
Acquisition costs		(2,696	)			(519	)			(3,471	)			(986	)
Fair value changes in financial instruments		865				407				(1,008	)			2,856
Fair value changes in business acquisition    contingencies		(353	)			3,510				45				3,531
Expenses related to financing transactions		—				—				(4	)			(7	)
Discontinuing Specialty Lab		(1,583	)	(1)		—				(4,019	)	(1)		—
Other losses or expenses		(82	)			(1,216	)	(2)		(216	)			(1,483	)	(2)
Net loss	$	(7,174	)		$	(7,751	)		$	(21,893	)		$	(15,287	)

__________________________

(1) Amounts consist of operating losses before depreciation related to the Discontinuing Specialty Lab.

(2) Amounts include costs associated with the closing of a lab.